[1] De Mattos-Arruda L, Caldas C. Cell-free circulating tumour DNA as a liquid biopsy in breast cancer[J]. Mol Oncol,2016,10(3):464-474.
[2] 陈小松, 沈坤炜. 乳腺癌“液体活检”: 血清标志物与循环肿瘤细胞的检测[J]. 分子诊断与治疗杂志,2012,4(6):410-414.
[3] Mandel P, Metais P.Les acides nuleiques du plasma sanguin chez l’homme[J]. CRSeances Soc Biol Fil,1948, 142:241-243
[4] Leon SA, Shapiro B, Sklaroff DM, et al.Free DNA in the serum of cancer patients and the effect of therapy[J]. Cancer Res,1977,37(3):646-650.
[5] Stroun M, Anker P, Maurice P, et al.Neoplastic characteristcs of the DNA found in the plasma of cancer patients[J]. Oncology,1989,46(5):318-322.
[6] Thakur BK, Zhang H, Becker A, et al.Double-stranded DNA in exosomes: a novel biomarker in cancer detection[J]. Cell Res,2014,24(6):766-769.
[7] Siravegna G, Marsoni S, Siena S, et al.Integrating liquid biopsies into the management of cancer[J]. Nat Rev Clin Oncol,2017,14(9):531-548.
[8] 叶青, 江泽飞. 循环肿瘤DNA检测在乳腺癌诊断中的临床应用[J]. 中国癌症杂志,2016,26(11):947-951.
[9] Sanmamed MF, Fernandez-Landazuri S, Rodriguez C, et al.Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors[J]. Clin Chem,2015,61(1):297-304.
[10] Watanabe M, Kawaguchi T, Isa S, et al.Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR[J]. Clin Cancer Res,2015,21(15):3552-3560.
[11] Zhu G, Ye X, Dong Z, et al.Highly sensitive droplet digital PCR method for detection of EGFR-activating mutations in plasma cell-free DNA from patients with advanced non-small cell lung cancer[J]. J Mol Diagn,2015, 17(3):265-272.
[12] Sacher AG, Paweletz C, Dahlberg SE, et al.Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer[J]. JAMA Oncol,2016,2(8):1014-1022.
[13] Pekin D, Skhiri Y, Baret JC, et al.Quantitative and sensitive detection of rare mutations using droplet-based microfluidics[J]. Lab Chip,2011,11(13):2156-2166.
[14] Oshiro C, Kagara N, Naoi Y, et al.PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients[J]. Breast Cancer Res Treat,2015, 150(2):299-307.
[15] Leary RJ, Kinde I, Diehl F, et al. Development of perso-nalized tumor biomarkers using massively parallel sequencing[J]. Sci Transl Med,2010,2(20):20ra14.
[16] Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing[J]. Sci Transl Med,2012, 4(162):162ra154.
[17] Wang TL, Maierhofer C, Speicher MR, et al.Digital ka-ryotyping[J]. Proc Natl Acad Sci U S A,2002,99(25):16156-16161.
[18] Paweletz CP, Sacher AG, Raymond CK, et al.Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients[J]. Clin Cancer Res,2016,22(4):915-922.
[19] Shaw JA, Page K, Blighe K, et al.Genomic analysis of circulating cell-free DNA infers breast cancer dormancy[J]. Genome Res,2012,22(2):220-231.
[20] Murtaza M, Dawson SJ, Pogrebniak K, et al.Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer[J]. Nat Commun,2015,6:8760.
[21] Murtaza M, Dawson SJ, Tsui DW, et al.Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA[J]. Nature,2013,497(7447):108-112.
[22] Guo S, Diep D, Plongthongkum N, et al.Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA[J]. Nat Genet,2017,49(4):635-642.
[23] Xu RH, Wei W, Krawczyk M, et al.Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater,2017,16(11):1155-1161.
[24] Umetani N, Giuliano AE, Hiramatsu SH, et al.Prediction of breast tumor progression by integrity of free circulating DNA in serum[J]. J Clin Oncol,2006,24(26):4270-4276.
[25] Stoetzer OJ, Fersching DM, Salat C, et al.Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin[J]. Cancer Lett,2013,336(1):140-148.
[26] Beaver JA, Jelovac D, Balukrishna S, et al.Detection of cancer DNA in plasma of patients with early-stage breast cancer[J]. Clin Cancer Res,2014,20(10):2643-2650.
[27] Page K, Guttery DS, Fernandez-Garcia D, et al.Next generation sequencing of circulating cell-free DNA for evaluating mutations and gene amplification in metastatic breast cancer[J]. Clin Chem,2017,63(2):532-541.
[28] Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med,2014,6(224):224ra24.
[29] Madhavan D, Wallwiener M, Bents K, et al.Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis[J]. Breast Cancer Res Treat,2014,146(1):163-174.
[30] Olsson E, Winter C, George A, et al.Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease[J]. EMBO Mol Med,2015,7(8):1034-1047.
[31] Dawson SJ, Tsui DW, Murtaza M, et al.Analysis of circulating tumor DNA to monitor metastatic breast cancer[J]. N Engl J Med,2013,368(13):1199-1209.
[32] Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer[J]. Sci Transl Med,2015,7(302):302ra133.
[33] Takahashi H, Kagara N, Tanei T, et al. Correlation of methylated circulating tumor DNA with response to neoadjuvant chemotherapy in breast cancer patients[J]. Clin Breast Cancer,2017,17(1):61-69.e3.
[34] Riva F, Bidard FC, Houy A, et al.Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer[J]. Clin Chem,2017,63(3):691-699.
[35] Guttery DS, Page K, Hills A, et al.Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer[J]. Clin Chem,2015,61(7):974-982.
[36] Schiavon G, Hrebien S, Garcia-Murillas I, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer[J]. Sci Transl Med,2015,7(313):313ra182.
[37] Gevensleben H, Garcia-Murillas I, Graeser MK, et al.Noninvasive detection of HER2 amplification with plasma DNA digital PCR[J]. Clin Cancer Res,2013,19(12):3276-3284.
[38] Bechmann T, Andersen RF, Pallisgaard N, et al.Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer[J]. J Cancer Res Clin Oncol,2013,139(6):995-1003.
[39] Appierto V, Di Cosimo S, Reduzzi C, et al.How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case[J]. Semin Cancer Biol,2017,44:106-116.
